NVS vs ISRG
Based on Invest's signal, Novartis AG (NVS) currently has the stronger Buy/Hold/Sell rating of the two — a buy versus sell for ISRG.
| Metric | NVS | ISRG |
|---|---|---|
| Price | $155.01 | $337.50 |
| Day change | -0.7% | +1.7% |
| Market cap | $294.6B | $120.9B |
| P/E ratio | — | 41.0 |
| 1-year return | +31.4% | -32.8% |
| Invest signal | Buy | Sell |
Higher market cap, higher 1-year return, lower P/E, and a stronger signal are highlighted. Data is for learning, not financial advice.
Can't decide? Trade both — risk-free.
Start with €1,000,000 in virtual cash and practice buying NVS and ISRG at live prices.
NVS vs ISRG: FAQ
Is NVS or ISRG the better stock to buy?
Based on Invest's signal, Novartis AG (NVS) currently has the stronger Buy/Hold/Sell rating of the two — a buy versus sell for ISRG. Remember that Invest's signal is a data-driven snapshot for learning, not financial advice — the best way to understand the difference is to add both to a watchlist and practice trading them with virtual cash.
Which is bigger, NVS or ISRG?
Novartis AG is the larger company by market capitalisation ($294.6B vs $120.9B).
Can I practice trading NVS and ISRG for free?
Yes. Invest is a free stock market simulator — you start with €1,000,000 in virtual cash and can buy and sell both NVS and ISRG at live market prices, with no real money and no risk. It runs in your browser and as a free iOS app.